Lexaria Bioscience (LEXX) Competitors $0.84 +0.02 (+2.14%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. RPTX, PYXS, ATRA, VNRX, CNTX, IRD, OTLK, CUE, ZIVO, and IZTCShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Repare Therapeutics (RPTX), Pyxis Oncology (PYXS), Atara Biotherapeutics (ATRA), VolitionRx (VNRX), Context Therapeutics (CNTX), Opus Genetics (IRD), Oncobiologics (OTLK), Cue Biopharma (CUE), ZIVO Bioscience (ZIVO), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors Repare Therapeutics Pyxis Oncology Atara Biotherapeutics VolitionRx Context Therapeutics Opus Genetics Oncobiologics Cue Biopharma ZIVO Bioscience Invizyne Technologies Lexaria Bioscience (NASDAQ:LEXX) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Is LEXX or RPTX more profitable? Repare Therapeutics has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Repare Therapeutics' return on equity of -78.25% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,849.19% -157.22% -133.69% Repare Therapeutics N/A -78.25%-66.85% Which has more risk & volatility, LEXX or RPTX? Lexaria Bioscience has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Does the media prefer LEXX or RPTX? In the previous week, Lexaria Bioscience had 2 more articles in the media than Repare Therapeutics. MarketBeat recorded 4 mentions for Lexaria Bioscience and 2 mentions for Repare Therapeutics. Repare Therapeutics' average media sentiment score of 0.52 beat Lexaria Bioscience's score of 0.48 indicating that Repare Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repare Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in LEXX or RPTX? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 11.5% of Repare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, LEXX or RPTX? Lexaria Bioscience has higher earnings, but lower revenue than Repare Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$460K35.59-$5.80M-$0.67-1.25Repare Therapeutics$53.48M1.25-$84.69M-$2.58-0.60 Do analysts recommend LEXX or RPTX? Lexaria Bioscience presently has a consensus price target of $4.00, indicating a potential upside of 377.90%. Repare Therapeutics has a consensus price target of $4.50, indicating a potential upside of 190.32%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryRepare Therapeutics beats Lexaria Bioscience on 9 of the 16 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.37M$3.13B$5.71B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-1.2520.9330.9125.26Price / Sales35.59231.60404.2188.28Price / CashN/A41.5625.2228.45Price / Book1.749.749.536.00Net Income-$5.80M-$54.74M$3.26B$265.34M7 Day Performance1.89%7.94%4.66%2.84%1 Month Performance-11.48%7.52%5.35%1.58%1 Year Performance-73.68%17.41%32.14%25.40% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience3.7814 of 5 stars$0.84+2.1%$4.00+377.9%-74.2%$16.37M$460K-1.257Short Interest ↓RPTXRepare Therapeutics2.6337 of 5 stars$1.54+0.3%$4.50+192.2%-46.4%$65.84M$53.48M-0.60180PYXSPyxis Oncology2.4145 of 5 stars$1.04-1.9%$8.67+733.3%-63.4%$65.67M$16.15M-0.6560News CoverageEarnings ReportAnalyst RevisionGap DownHigh Trading VolumeATRAAtara Biotherapeutics4.6169 of 5 stars$10.32-5.8%$20.00+93.8%+75.3%$65.31M$128.94M-2.77330Positive NewsEarnings ReportVNRXVolitionRx2.1789 of 5 stars$0.63-2.6%$3.50+460.0%+16.4%$64.99M$1.31M-1.7480Analyst ForecastGap UpCNTXContext Therapeutics3.5185 of 5 stars$0.68-5.9%$5.25+675.3%-69.9%$64.57MN/A-1.887Short Interest ↓IRDOpus Genetics1.8568 of 5 stars$1.06-0.9%$7.33+591.8%N/A$63.84M$10.99M-0.5014News CoverageEarnings ReportOTLKOncobiologics1.8293 of 5 stars$1.96+3.2%$9.60+389.8%-69.6%$63.78MN/A-2.1520News CoverageEarnings ReportAnalyst ForecastGap UpCUECue Biopharma4.5026 of 5 stars$0.83+0.0%$4.00+381.1%+21.6%$62.62M$9.29M-1.2460Earnings ReportZIVOZIVO Bioscience0.2462 of 5 stars$16.21+11.9%N/A+115.5%$61.87M$15.85K-3.3210IZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029Gap Down Related Companies and Tools Related Companies RPTX Competitors PYXS Competitors ATRA Competitors VNRX Competitors CNTX Competitors IRD Competitors OTLK Competitors CUE Competitors ZIVO Competitors IZTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access